Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fulcrum, and adidas and Encourages Investors to Contact the Firm
May 03, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
Brain Scientific Inks Deal with Fulcrum to Go After At-Home Diagnostic Space, Hires VP of Marketing and Communications
December 01, 2022 10:23 ET
|
Brain Scientific Inc.
LAKEWOOD RANCH, Fla., Dec. 01, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific (OTCQB:BRSF), a Florida-based applied science technology company, announces today a new distribution...
Monte Harrick and Sam Robert of Fulcrum Partners Will Be Featured Presenters at NAIFA-FSP Advanced Financial Planning Symposium
May 24, 2022 09:00 ET
|
Fulcrum Partners, LLC
ATLANTA, May 24, 2022 (GLOBE NEWSWIRE) -- Monte Harrick and Sam Robert will represent Fulcrum Partners, a OneDigital Company, as featured presenters at the NAIFA-FSP 2022 Advanced Practice...
Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020
February 28, 2020 07:00 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
November 14, 2019 07:00 ET
|
Fulcrum Therapeutics
– Announced preliminary results of a Phase 1 clinical trial of losmapimod in FSHD patients – – Initiated IND-enabling studies for FTX-6058 for the potential treatment of sickle cell disease and...
Fulcrum Therapeutics to Present at the Stifel 2019 Healthcare Conference
November 13, 2019 08:01 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
November 06, 2019 08:01 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Host Key Opinion Leader Breakfast Symposium on Facioscapulohumeral Dystrophy (FSHD), on November 7, 2019
October 31, 2019 08:00 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD
October 04, 2019 04:30 ET
|
Fulcrum Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Multiple Presentations of Losmapimod Data at World Muscle Society Meeting
October 01, 2019 07:00 ET
|
Fulcrum Therapeutics
Oral presentation to highlight Phase 1 data on safety, tolerability and target engagement of losmapimod in treatment of FSHDCompany also announces updated preclinical data on FTX-6058 for potential...